跳至主要内容
临床试验/JPRN-UMIN000002570
JPRN-UMIN000002570已完成2 期

Phase II study of weekly amrubicin in patients with refractory or relapsed non-small cell lung cancer - Phase II study of weekly amrubicin for non-small cell lung cancer patients

ational Hospital Organization Nagoya Medical Center0 个研究点目标入组 43 人开始时间: 2009年10月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
43

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Contraindication for amrubicin 2. Carcinomatous pleuritis, pericarditis, peritonitis and other metastasis with local therapy indication 3. Patient can not enroll during radiotherapy, but can be registered after interval (chest: four weeks; without chest: one weeks). 4. Serious medical complication: Uncontrolled angina pectoris, myocardial infarction for less than 3 months, patient with cardiac failure. Uncontrolled diabetes mellitus, hypertension. 5. Infected patients 6. Other clinical difficulties in this study

研究者

发起方
ational Hospital Organization Nagoya Medical Center

相似试验

Phase II study of weekly amrubicin in patients with... | 临床试验